
From Local to Landmark: Scientologists Dedicate the Historical Site of the First Dianetics Foundation
Nestled in a quiet part of Elizabeth, New Jersey, is an unassuming, three-story building—a structure that once unquestionably became the nexus of a global awakening.
Just 15 miles from New York City, this rejuvenated Colonial-Revival setting at 42 Aberdeen Road now joins the distinguished ranks of L. Ron Hubbard (LRH) Landmark Sites around the world.
During a spring afternoon celebration attended by Scientologists, community leaders and restoration specialists, guests weren't just honoring a historic moment. In fact, they were able to take the very first steps inside the exact rooms where Mr. Hubbard had personally taught the first Dianetics auditors, delivered the first Dianetics lectures and set in motion the first Dianetics Research Foundation.
'To be here, at this historic site on L. Ron Hubbard's path of discovery, is an honor and in a class of its own,' one guest said.
Now completely restored to its 1950 appearance, 42 Aberdeen Road is more than a building, it is the precise cornerstone where the world first turned a page and a revolution of the human mind all began.
With the May 9, 1950 publication of Dianetics: The Modern Science of Mental Health, what unfolded within these walls was nothing short of explosive—as the book began its unprecedented run of 28 weeks on the New York Times bestseller list. Almost overnight, crowds from across America began arriving without invitation, eager to meet and learn in person from the author of what was rapidly becoming the most popular book ever written on the human mind.
This site of universal influence now stands as it once did—complete with original furniture, vintage crystal doorknobs and refinished wood floors with mahogany Celtic pattern inlays. All have been restored to their glorious past, including the desk where Mr. Hubbard once wrote and the fireplace before which students gathered.
The Remington typewriter and SoundScriber dictation recorders Mr. Hubbard worked with are also on display—even his prized Ford Deluxe 'Woody' Wagon is parked outside.
Officiating the ceremony was the Church of Scientology Preservationist who oversaw the meticulous restoration. 'This site became the epicenter of a movement—one that grew from Dianetics, the first workable science of the mind, into the Scientology religion, with Churches and Missions spanning the globe,' he said. 'And for the first time, beginning today, you will be able to walk inside and stand right where it all began!'
Fittingly, and just days before the 75th Anniversary of the publication of Dianetics, dignitaries honoring the site's Grand Opening spoke of the impact of L. Ron Hubbard, both locally and globally.
The day's first guest speaker, Ms. Jennifer Costa, President and CEO of the Greater Elizabeth Chamber of Commerce, welcomed the opening as a milestone for the city. 'Here in Elizabeth, we pride ourselves on a theme that we think says everything: 'It all starts here.' And that is so very true. Elizabeth is a city of many firsts—from the first capital of the state of New Jersey to the home of our first governor and even the first submarine. Well, today we stand here in front of this breathtaking site, another first that claims Elizabeth with pride as the very place where the first Dianetics Foundation was born. We can't wait to welcome all of you to this landmark that belongs to all of us—because this is where your history and our history meet—right here at 42 Aberdeen Road.'
Mr. Thomas B. Connolly, who served as historical architect on the project, emphasized the importance of preserving the site's original character. 'Working with your team to restore this landmark was a dream. Your commitment to quality and authenticity was evident from day one and your goal was clear: to return the site to exactly how it was when Mr. Hubbard was here. As just a single example, when we peeled back the white aluminum siding that had been on the façade for decades, we uncovered a century-old surprise: the original cedar shingles, right where they had been since 1910.' Mr. Connolly added, 'And that's only one of the countless details that brought this heritage site back to life, transforming it into what you see today: the gem of the block!'
Dr. Apostle Lemmew Samuel, Founder of an Evangelical Assembly in New York City, has spent a lifetime in religious service—and spoke to the spiritual power of the Landmark Site. 'Just like those first readers who drove here back in 1950 to learn from Mr. L. Ron Hubbard himself, I now find myself on the same doorstep, drawn by the same truth from the pages of Dianetics,' Dr. Samuel said. 'I'm just getting started with Dianetics. But I know I have in my hands a way to help the people I serve—couples in crisis, youth searching for direction, anyone trying to hold their life together. I can help them find their way out of the darkness of the mind and into the light!'
Dr. Monica Sanchez, a United Nations Cultural Ambassador and Humanitarian, spoke not just of the legacy of this storied location, but of the enduring imprint L. Ron Hubbard left on Mankind. 'Sometimes we think we know the way, until life gives you a detour—one without signs. But Mr. Hubbard's work says: Here's another road. Here's the best road. That's why I call L. Ron Hubbard a GPS for humanity,' she said to the crowd. 'If I had been here on Aberdeen Road back in 1950, I would have told him: 'Take me as your student!' I would have felt very privileged just to learn by his side. But, thanks to everything he left behind and your incredible work to preserve it, we can all be his students.'
Captain Steve Nagiewicz, Executive Director Emeritus of the world-famous Explorers Club—where Mr. Hubbard was an exalted member and carried three official expedition flags—praised LRH's work as nothing short of bold discovery. 'Mr. Hubbard explored the oceans, he crossed continents, he set a course for distant stars. But his final frontier was the most uncharted territory of all: conducting a journey inside the human mind,' he said. 'Exploring the unknown, living on the edge, going where no one has gone before … it requires a rock-solid state of mind, leaving no margin for error.' Mr. Nagiewicz added, 'It's my hope that this day and this site will always remind us to push farther, reach deeper, keep exploring. And as future explorers venture to the stars, no doubt L. Ron Hubbard will be with them in spirit!'
Historic 42 Aberdeen Road has a sister in Bay Head, New Jersey, 50 miles away, where LRH wrote Dianetics. Mr. Hubbard worked in both locations during the same time period, in Bay Head for part of the year and Elizabeth for the other. The Bay Head property was previously opened as an L. Ron Hubbard Landmark Site in 2011—Mr. Hubbard's centennial year.
All told, there are seven such Landmark Sites now open on three continents around the world, including L. Ron Hubbard's heritage site at the base of Camelback Mountain in Phoenix, Arizona—known as the Birthplace of Scientology; the original Founding Church that Mr. Hubbard established in Washington, DC; the original Hubbard Communications Office on Fitzroy Street in London, England; his Linksfield Ridge estate overlooking Johannesburg, South Africa; and his headquarters at Saint Hill in East Grinstead, England.
Each Landmark Site offers a literal and visual history of the work and advances Mr. Hubbard achieved during the time he was at that particular location. Each also features a room devoted to the wider story of Mr. Hubbard's life of global exploration and research—including his revolutionary work here in Elizabeth, New Jersey. In full, the sites mark Mr. Hubbard's progressive steps to the founding of Dianetics and Scientology.
Two more Landmark Sites are set to open by this summer—one in the US and another in Southern Africa—carrying forward the legacy of places like 42 Aberdeen Road, a global tribute that echoes for generations to come.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
5 days ago
- Malaysian Reserve
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide. 'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.' Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms. The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@


Malaysian Reserve
6 days ago
- Malaysian Reserve
NASA's SpaceX Crew-11 Mission to Advance Stem Cell Manufacturing and In-Orbit Data Processing
Crew members will support ISS National Lab-sponsored investigations with important applications in regenerative medicine, advanced materials, and edge computing KENNEDY SPACE CENTER, Fla., July 30, 2025 /PRNewswire/ — Four astronauts are set to launch to the International Space Station (ISS) as part of NASA's SpaceX Crew-11 mission. Over the coming months, the crew will support research to produce stem cells in space, study engineered liver tissue, and advance in-orbit data processing. The mission is scheduled to launch no earlier than 12:09 p.m. EDT on July 31, 2025, from NASA's Kennedy Space Center in Florida. NASA astronauts Zena Cardman (commander) and Mike Fincke (pilot), along with Japan Aerospace Exploration Agency (JAXA) astronaut Kimiya Yui (mission specialist) and Roscosmos cosmonaut Oleg Platonov (mission specialist), will serve as part of the Expedition 73 and 74 crew. During the mission, the crew will work on several payloads sponsored by the ISS National Laboratory® to benefit humanity and foster a robust economy in low Earth orbit (LEO). Below are some ISS National Lab-sponsored investigations the crew is expected to work on. Two projects focus on the production of stem cells in space to improve their maturation into different types of tissues. Research teams at Cedars-Sinai Medical Center and the University of Colorado will determine whether stem cells grow faster in space, resulting in larger numbers of cells for therapies to treat conditions like heart disease, neurodegenerative diseases, and more. A project from the Wake Forest Institute for Regenerative Medicine will study engineered liver tissue containing blood vessels in microgravity. Results from the project, which was part of NASA's Vascular Tissue Challenge, could lead to new regenerative therapies for patients on Earth and, eventually, to the production of human tissues in space for organ transplants. New York high school students Isabelle Chuang and Julia Gross, winners of the 2024 Genes in Space™ competition, aim to use phages—viruses that attack bacteria—as therapeutic agents to combat microbial infections in space. Genes in Space, founded by Boeing and miniPCR bio and supported by the ISS National Lab, invites students in grades 7-12 to propose pioneering DNA experiments that leverage the unique environment of the space station. The ISS National Lab has a longstanding partnership with the U.S. National Science Foundation (NSF) to support fundamental research in LEO, and multiple NSF-funded projects will launch in the coming months. One such investigation from the University of California, Berkeley will study how tiny particles move within a liquid droplet and then stick to the droplet's surface. Understanding this process is useful for many things like producing advanced materials and removing pollutants in the environment. A project from Axiom Space, an ISS National Lab Commercial Service Provider, and Red Hat, a leading provider of open-source solutions, seeks to increase in-orbit data storage and edge-processing capabilities with the Red Hat Device Edge platform. These capabilities would enable near real-time analytics to support scalable expansion and iteration of experiments while they operate in space—which will be paramount to scaling R&D and manufacturing on future space platforms. This mission is the 11th SpaceX crew rotation to the orbiting laboratory as part of NASA's Commercial Crew Program. To learn more about the ISS National Lab, including research and technology demonstrations that have flown on previous missions, visit our launch page. Download a high-resolution image for this release: NASA's SpaceX Crew-11 About the International Space Station (ISS) National Laboratory:The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space® (CASIS®) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website. As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page. Media Contact: Patrick O'Neill 904-806-0035 PONeill@ International Space Station (ISS) National Laboratory Managed by the Center for the Advancement of Science in Space® (CASIS®) __________________________________________________________________________1005 Viera Blvd., Suite 101, Rockledge, FL 32955 • 321.253.5101 •


Malaysian Reserve
28-07-2025
- Malaysian Reserve
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ — Antengene Corporation Limited ('Antengene', SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate)Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)Abstract Number: 2907Presentation Number: 2113PDate: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ('Antengene', SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of 'Treating Patients Beyond Borders'. Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Mobile: +86 13062747000